Human immunodeficiency virus
Conditions
Brief summary
· Proportion of participants that develop Grade 3 or 4 treatment-related adverse events or laboratory abnormalities during the study, based on the CTCAE v5.0 grading scale., · Proportion of SAMHD1 phosphorylation in CD4+ T cells upon in-vitro T cell activation at weeks 0, 2, 12, 24, 28, 36 and 48.
Detailed description
Antiviral effect of dasatinib and its durability:Proviral reactivation capacity upon in-vitro T-cell activation, Resistance to HIV infection, Homeostatic proliferation, Immunomodulatory effects, Impact of dasatinib and its durability on: Inflammation and immune activation, HIV-1 reservoir, CD4+ T cell populations, Pharmacokinetics of dasatinib: · Dasatinib concentrations in plasma at weeks 0, 2, 12 and 24.
Interventions
DRUGDasatinib/Teva 50 mg επικαλυμμένα με λεπτό υμένιο δισκία
Sponsors
Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| · Proportion of participants that develop Grade 3 or 4 treatment-related adverse events or laboratory abnormalities during the study, based on the CTCAE v5.0 grading scale., · Proportion of SAMHD1 phosphorylation in CD4+ T cells upon in-vitro T cell activation at weeks 0, 2, 12, 24, 28, 36 and 48. | — |
Secondary
| Measure | Time frame |
|---|---|
| Antiviral effect of dasatinib and its durability:Proviral reactivation capacity upon in-vitro T-cell activation, Resistance to HIV infection, Homeostatic proliferation, Immunomodulatory effects, Impact of dasatinib and its durability on: Inflammation and immune activation, HIV-1 reservoir, CD4+ T cell populations, Pharmacokinetics of dasatinib: · Dasatinib concentrations in plasma at weeks 0, 2, 12 and 24. | — |
Countries
Spain
Outcome results
None listed